A Dose Escalation Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs RG 6146 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Roche; Tensha Therapeutics
- 10 Nov 2017 Status changed from recruiting to completed.
- 23 Jun 2017 Planned number of patients changed from 68 to 51.
- 23 Jun 2017 Planned End Date changed from 31 Aug 2017 to 30 Apr 2018.